tiletamine hydrochloride has been researched along with Intestinal Diseases in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aoyagi, T; Fukai, M; Furukawa, H; Jomen, W; Ozaki, M; Suzuki, T; Todo, S; Ueki, S; Umezawa, K; Yamashita, K | 1 |
1 other study(ies) available for tiletamine hydrochloride and Intestinal Diseases
| Article | Year |
|---|---|
The novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin, prevents local and remote organ injury following intestinal ischemia/reperfusion in rats.
Topics: Animals; Anti-Inflammatory Agents; Benzamides; Cyclohexanones; Disease Models, Animal; Intestinal Diseases; Lung Diseases; Male; NF-kappa B; Rats; Rats, Sprague-Dawley; Reperfusion Injury | 2008 |